Videos

Oncology nurses should have open communication with patients and closely monitor their hemoglobin levels when dealing with patients with myelofibrosis who have or may have anemia.

Jennifer Cargile, MEd, CCC-SLP, shares some examples of how she helped patients continue their daily activities while they experienced symptoms of cancer-related cognitive impairment.

According to Charina Toste, DNP, APRN-C, AOCNP, MSN, BSN, RN, patients with newly diagnosed myeloproliferative neoplasms may be unaware of the questions they should be asking their providers.

Lindsey Lyle, PA-C, MS, discusses how oncology nurses can work with their patients to determine if symptoms are related to their myeloproliferative neoplasm or another health condition.

Meredith Cummings BSN, RN, OCN, highlights her research on machine learning and its potential application in optimizing symptom management.

Alyssa Ridad BSN-RN, OCN; and Amanda McKaig, BSN, RN, OCN, discuss oncology nurse perceptions of medical cannabis.

Yelena Shames, MSA, ACNP-BC, CNRN, discusses when immune checkpoint inhibitor treatment should be paused because of laboratory abnormalities.

Johanna Garibaldi, BSN, RN, EMT-P, discusses how a mobile clinic improved cancer screening rates among local firefighters.

Elizabeth R. Cullen, MSN, ARNP, provides an overview of avasopasem manganese and its potential role in reducing severe oral mucositis for patients undergoing radiotherapy.

Seth Eisenberg, ASN, RN, OCN, BMTCN, discusses his research comparing plastic-backed pads and the Splashblocker.

Patricia Jakel, RN, MN, AOCN, underscores some of the challenges nurses face when promoting adherence to oral medications.

Kellie Zeichner BSN, RN, OCN, explains how her institution created a standardized monitoring procedure for insulinoma care.

Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.

Kara Morris, MSN, RN, OCN; and Christine Wylie, MSN, RN, OCN, discuss the benefits of oral cryotherapy for patients receiving dose-dense doxorubicin.

Melanie Darvish, BSN, RN, shares her experience attending the Oncology Nursing Society (ONS) Congress with an ONS Scholarship.

AnnMarie Walton, PhD, MPH, RN, OCN, CHES, FAAN, discusses her research on plastic-backed pads and discusses the importance of better methods to reduce exposure to antineoplastic drug residue.

Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, discuss their research on wearable technology.

Heather Niccum Haag, BSN, RN, CCRN, shares her experience creating an educational resource for her patients with Von-Hippel Lindau tumors who are receiving belzutifan.

Elizabeth Loach, MSN, APRN, CNS, AGCNS-BC, OCN, discusses the importance of including frontline nurses in nursing leadership task forces.

Oncology nurse investigators from Dana-Farber discuss the value of weighted blankets in reducing patient anxiety during infusions.

Jessica MacIntyre, DNP, MBA, APRN, NP-C, AOCNP, discusses ways to standardize the process of referring patients to the Leukemia and Lymphoma Society.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, highlights how her unit leveraged an educational video to improve compliance with double verification for high-alert medications.

Eric Zack, DNP, RN, ACNP-BC, AOCN, BMTCN, describes disseminated intravascular coagulation and best nursing strategies to mitigate the severity of this condition.

Donna Catamero, ANP-BC, OCN, CCRC, outlines best management strategies for treating patients receiving teclistamab who experience cytokine release syndrome.

Hilda Haynes-Lewis, PhD, ANP-BC, AOCNP; and Rosaleen Bloom PhD, APRN, ACNS-BC, AOCNS, discuss the ways a cancer diagnosis can impair an individual’s ability to work normally.

Meghan K. Berkenstock, MD, discusses the growing need for strong collaboration between ophthalmologists and gynecologic oncology care teams.

Mary Katherine Montes de Oca, MD, discusses the potential benefit of cryocompression therapy in preventing peripheral neuropathy in patients with gynecologic cancers who are receiving chemotherapy.

Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.